“I shouldn’t say this openly, but I want to drive us out of business if I could.”
That is how Hanan Balkhy, Saudi Arabia’s nominee for WHO Director-General, described her end goal to delegates in Geneva — helping countries graduate from external aid altogether. Her words closed a two-day candidates’ forum that ended Thursday, November 19, with seven contenders still split on how to fund the cash-strapped agency.
The forum, held ahead of January’s Executive Board shortlist decision, brought all seven candidates before member states for 43 questions across three final sessions on Thursday alone, Health Policy Watch reported. The outcome matters far beyond Geneva: the next Director-General will steer how the world funds, coordinates and trusts health science at a moment when aid budgets are shrinking and the agency’s authority is under strain.
Thursday’s closing session pitted three distinct prescriptions against each other: Indonesia’s former banker Budi Gunadi Sadikin, Spain’s longtime WHO environment chief María Neira, and Balkhy, a regional director with a record of crisis management. Each answered for hours. Each left with a different answer to the same question — who pays for global health now?
“WHO make[s] you healthy, [the] World Bank make[s] you wealthy,” Sadikin told delegates, urging closer cooperation between the two institutions. Drawing on his banking background, he argued global health does not lack money; health ministers simply struggle to translate national plans into returns finance ministries understand.
Sadikin cited more than $8.7 billion mobilised for Indonesia and claimed a single call to the Asian Development Bank’s president helped the Philippines secure $1.2 billion, Health Policy Watch reported. As Director-General, he pledged to help ministers build single national plans and convene development-bank experts to fund them — plus pooled procurement to replicate the Pan American Health Organization’s Revolving Fund and cut vaccine and cancer-drug prices alongside Gavi and UNICEF.
But there is a catch. Pressed on binding benefit-sharing rules in the Pathogen Access and Benefit-Sharing (PABS) annex, Sadikin avoided committing, favouring what he called “reasonable” rather than “abusive” investor returns.
And when asked how an outsider without clinical training would safeguard WHO’s scientific independence, he leaned into the gap rather than papering over it. “I have no intention to be the smartest [person] in the room,” he said, framing his job as funding scientists and shielding them from politics.
Neira took the opposite view of money. “WHO’s authority has never come from the size of its budget,” she told delegates. “WHO’s authority comes from evidence.” After two decades leading WHO’s environment and climate work, she argued that tackling environmental risks could prevent a quarter of global disease and death — “around 13 million deaths every year,” including more than seven million linked to air pollution and climate change.
Her method costs little, she argued: package health data for energy, transport and agriculture ministries and let them act. She credited London’s ultra-low emission zone with cutting air-pollution mortality by 40 percent, and pointed to China’s falling pollution alongside rising GDP.
On internal reform, she promised “radical reform” and “precision surgery,” a “One WHO” alignment of headquarters, regional and country offices in her first year, and clearing what she called an “unacceptable” backlog of internal justice cases. Yet Health Policy Watch noted what she avoided: naming what WHO itself would surrender.
Balkhy, by contrast, offered discipline rather than vision. She asked delegates to judge her on “six tests of delivery,” with reporting within 100 days, annually, and at the end of her term. As proof, she described freezing recruitments on arrival at her regional office, merging three dispersed immunisation and polio units, and tying senior posts to competitive selection and delivery compacts.
Hanan Balkhy told delegates that she wanted to drive the organization out of business if she could, framing her goal around country self-reliance.
Her regional record carried the numbers: $1.6 billion mobilised in 2024–2025, with 90 percent reaching country level, plus $153 million from the Pandemic Fund and new Islamic faith-based financing, Health Policy Watch reported. On politically sensitive ground she turned cautious — pressed by Australia on sexual and reproductive health and rights, she avoided the phrase entirely, promising science-based guidelines applied under national policies.
Where the seven split — and the money table
Beneath the consensus on scientific independence and country-level delivery, the field divided cleanly along career lines. Three WHO insiders — Hans Kluge, Balkhy and Neira — pitched institutional experience. Three national health leaders — Qatar’s Al Kuwari, Sadikin and Song — leaned on domestic delivery records. Tamamyan stood alone as a clinical outsider, nominated cross-regionally by Botswana to challenge bloc politics, Health Policy Watch reported.
| Candidate | Financing pitch | Accountability offer |
|---|---|---|
| Budi Gunadi Sadikin (Indonesia) | Development-bank leverage, pooled procurement | None comparable to 100-day plans |
| María Neira (Spain) | Evidence over budget size, cross-sector persuasion | Judged after one year on efficiency and culture |
| Hanan Balkhy (Saudi Arabia) | Faith-based financing coalitions, country self-reliance | 100-day reporting, delivery compacts |
| Al Kuwari (Qatar) | WHO Foundation, unearmarked funds | Functional review |
| Tamamyan (Botswana-nominated) | Mass public giving, outreach to Washington | Annual public reporting assessed by Executive Board |
| Kluge / Song | Institutional and domestic delivery records | Kluge: member-state review in first months; Song: none stated |
On pandemic equity, all seven backed expanding regional manufacturing and most urged finishing the PABS annex, but they split on how hard to push industry. Al Kuwari urged completing PABS by May. Kluge vowed to summon pharma chiefs to Geneva. Song backed voluntary licensing through the Medicines Patent Pool, while Neira argued WHO’s role is accelerating access rather than transferring technology directly.
Malaysia’s delegation played along after missing out on several earlier draws, thanking the chair “for finally picking Malaysia,” while the important thing, delegates were reminded, is the substance behind each question.
Sadikin’s path to Geneva has few precedents. Born in 1964, he is a nuclear physicist by training, holding an engineering physics degree from the Bandung Institute of Technology earned in 1988, and began his career at IBM Asia Pacific in Tokyo before turning to banking, where he rose to chief executive of Indonesia’s largest bank, Bank Mandiri, in 2013.
He took over the health ministry in December 2020 with no medical or public health background — only the second health minister in the country’s history without a medical degree — and led it through the COVID-19 pandemic. He is also one of the architects of the World Bank-hosted Pandemic Fund, launched in Bali in 2022.
The next step is on the record: the Executive Board shortlists candidates in January, and the final choice will determine whether WHO’s next era is financed by banks, evidence or discipline.